Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast Cancer


In Partnership With:

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Julia Foldi, MD, PhD, assistant professor of medicine, Hematology/Oncology, Department of Medicine, University of Pittsburg Medical Center (UPMC), University of Pittsburg Medical Center, breast medical oncologist, UPMC Hillman Cancer Center, discusses the evolving role of fam-trastuzumab deruxtecan-nxki (Enthertu; T-DXd) in the treatment of metastatic HER2-positive breast cancer.

Within the HER2-positive setting there is also the HER2-low setting, which can make treatment navigation even more complicated, Foldi begins. In HER2-positive disease, T-DXd is the current standard of care (SOC) in the second-line setting following progression on standard, first-line pertuzumab (Verzenio), trastuzumab (Herceptin), and docetaxel, Foldi begins. In the phase 3 DESTINY-Breast03 trial (NCT03529110), T-DXd demonstrated a significant progression-free survival (PFS) and overall survival (OS) benefit over the prior SOC, ado-trastuzumab emtansine (Kadcyla; T-DM1), and was accordingly established as the preferred second-line treatment option, Foldi reports.

Prior trials such as the phase 2 DESTINY-Breast01 (NCT03248492) and phase 3 DESTINY-Breast02 (NCT03523585) studies had already positioned T-DXd as an effective treatment in later lines of therapy, demonstrating its efficacy and tolerability in more advanced stages of the disease, Foldi explains. IN DESTINY-Breast01, T-DXd generated superior response rates in a heavily pretreated patient population; T-DXd also produced superior efficacy vs physician's choice of chemotherapy in the third-line and beyond in the DESTINY-Breast02 trial, she says. Foldi emphasizes that the DESTINY-Breast03 trial expanded on these findings by confirming T-DXd's role in earlier lines of therapy.

Ongoing research is exploring the potential use of T-DXd in earlier treatment lines, including the first-line setting, Foldi continues. An ongoing trial will compare T-DXd with taxane-based chemotherapy and HER2-targeting antibody combinations. This approach reflects a broader effort to optimize treatment strategies and leverage the benefits of T-DXd across different stages of HER2-positive breast cancer, Foldi explains.

Overall, T-DXd's emergence represents a significant advancement in the therapeutic landscape, improving outcomes for patients with HER2-positive breast cancer, especially those facing disease progression after initial therapies.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD